A primary care focus on the treatment of patients with major depressive disorder

American Journal of the Medical Sciences

Volumn 342, Issue 4, 2011, Pages 324-330

  Weihs, Karen ^a   Wert, Jonathan M ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b BlueSpark Healthcare Communications   (United States)

Author keywords

Antidepressant treatment; Collaborative care; Depression; Major depressive disorder; Somatic interventions

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; ISOCARBOXAZID; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

BLOOD PRESSURE; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSTHYMIA; FLUSHING; GENERAL PRACTITIONER; HEART ARRHYTHMIA; HUMAN; HYPERTENSIVE CRISIS; HYPOMANIA; HYPOTENSION; MAJOR DEPRESSION; MANIA; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PSYCHOTHERAPY; QUESTIONNAIRE; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; URINE RETENTION; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 80053357053     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318210ff56     Document Type: Review

References (65)

1. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27. (Pubitemid 40973437)
2. National Institute of Mental Health. The numbers count: mental disorders in America. Available at: http://www.nimh.nih.gov/health/ publications/the- numbers-count-mental-disorders-in-america/index. shtml. Last updated August 10, 2009. Accessed April 26, 2010.
3. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105. (Pubitemid 37432885)
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
5. Simon GE. Long-term prognosis of depression in primary care. Bull World Health Organ 2000;78:439-45. (Pubitemid 30367597)
6. Vittengl JR, Clark LA, Jarrett RB. Deterioration in psychosocial functioning predicts relapse/recurrence after cognitive therapy for depression. J Affect Disord 2009;112:135-43.
7. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64:327-37. (Pubitemid 46376789)
8. Kornum BR, Weikop P, Moller A, et al. Serotonin depletion results in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. Brain Res 2006;1073-1074:262-8.
9. Kusmider M, Faron-Gorecka A, Dziedzicka-Wasylewska M. Delayed effects of antidepressant drugs in rats. Behav Pharmacol 2006; 17:641-9.
10. Moreno FA, Heninger GR, McGahuey CA, et al. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry 2000;48:327-9. (Pubitemid 30645805)
11. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a metaanalysis of monoamine depletion studies. Mol Psychiatry 2007;12: 331-59. (Pubitemid 46496835)
12. Kessler RC. The effects of stressful life events on depression. Annu Rev Psychol 1997;48:191-214. (Pubitemid 127485175)
13. Moran PM, Bifulco A, Ball C, et al. Predicting onset of depression: the Vulnerability to Depression Questionnaire. Br J Clin Psychol 2001;40:411-27. (Pubitemid 33080897)
14. Mark TL, Levit KR, Buck JA. Psychotropic drug prescriptions by medical specialty. Psychiatr Serv 2009;60:1167.
15. Department of Veterans Affairs, Department of Defense. VA/DoD clinical practice guideline for management of major depressive disorder (MDD). Washington (DC): Department of Veterans Affairs, Department of Defense 2009. Available at http://www.healthquality.va.gov/ mdd/mdd-full09-c.pdf. Last updated May 2009. Accessed April 26, 2010.
16. Arsenault-Lapierre G, Kim C, Turecki G. Diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry 2004;4:37-48.
17. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a metaanalysis. Psychosom Med 2004;66:802-13. (Pubitemid 39552862)
18. Vaccarino V, McClure C, Johnson BD, et al. Depression, the metabolic syndrome and cardiovascular risk. Psychosom Med 2008;70: 40-8.
19. Kimmel PL, Peterson RA, Weihs KL, et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000;57:2093-8. (Pubitemid 30252302)
20. Mykletun A, Bjerkeset O, Dewey M, et al. Anxiety, depression, and cause-specific mortality: the HUNT study. Psychosom Med 2007;69: 323-31. (Pubitemid 46800292)
21. Agency for Healthcare Research and Quality. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Available at: http://effectivehealthcare.ahrq. gov/healthInfo.cfm? infotype-rr&ProcessID-7%20&DocID-61. Last updated January 24, 2007. Accessed April 26, 2010.
22. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among secondstep antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008;65:870-80.
23. Agency for Healthcare Research and Quality. Choosing antidepressants for adults: clinicians guide. Available at: http://effectivehealthcare. ahrq.gov/healthInfo.cfm?infotype-sg&DocID-9&ProcessID-7. Last updated August 15, 2007. Accessed April 26, 2010.
24. Karasu TB, Gelenberg A, Merriam A, et al; for the American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder, 2nd ed. Available at: http://www. psychiatryonline.com/ pracGuide/pracGuideChapToc-7.aspx. Last updated 2000. Accessed April 26, 2010.
25. Rost K, Nutting P, Smith JL, et al. Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care. BMJ 2002;325:934-9.
26. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
27. Dodd S, Williams LJ, Jacka FN, et al. Reliability of the Mood Disorder Questionnaire: comparison with the Structured Clinical Interview for the DSM-IV-TR in a population sample. Aust N Z J Psychiatry 2009;43:526-30.
28. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13. (Pubitemid 32823891)
29. Rush AJ, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986;18: 65-87. (Pubitemid 16085767)
30. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26:477-86. (Pubitemid 26142491)
31. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54: 573-83. (Pubitemid 37289444)
32. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33. (Pubitemid 29001829)
33. Lowe B, Unu tzer J, Callahan CM, et al. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care 2004;42:1194-201. (Pubitemid 39627296)
34. Leon AC, Solomon DA, Mueller TI, et al. A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. Am J Psychiatry 2003;160:727-33. (Pubitemid 41079606)
35. Fochtmann LJ, Gelenberg AG. Guideline watch: practice guideline for the treatment of patients with major depressive disorder, 2nd ed. Available at: http://www.psychiatryonline.com/content.aspx? aid-148217. Last updated September 2005. Accessed April 26, 2010.
36. Demyttenaere K, Jaspers L. Bupropion and SSRI-induced side effects. J Psychopharmacol 2008;22:792-804.
37. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008;149:734-50.
38. Eli Lilly and Company. Cymbalta® (duloxetine hydrochloride) full prescribing information. Available at: http://www.cymbalta.com/index. jsp. Last updated January 2010. Accessed April 26, 2010.
39. Wyeth Pharmaceuticals Inc. Pritiq® (desvenlafaxine) full prescribing information. Available at: http://www.wyeth.com/content/showlabeling. asp?id-497. Last updated February 2010. Accessed April 26, 2010.
40. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 2005;27:1685-95. (Pubitemid 41815222)
41. US Food and Drug Administration. FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2004/ ucm108363.htm. Last updated October 15, 2004. Accessed April 26, 2010.
42. US Food and Drug Administration. FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ ucm108905.htm. Last updated May 2, 2007. Accessed April 26, 2010.
43. Henshall DC, Durmu ller N, White HS, et al. Electroencephalographic and behavioral convulsant effects of hydrobromide and hydrochloride salts of bupropion in conscious rodents. Neuropsychiatr Dis Treat 2009;5:189-206.
44. James LP, Farrar HC, Griebel ML, et al. Bromism: intoxication from a rare anticonvulsant therapy. Pediatr Emerg Care 1997;13:268-70. (Pubitemid 27374162)
45. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2009;42:57-90.
46. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-53. (Pubitemid 47015482)
47. Eli Lilly and Company. Symbyax® (olanzapine and fluoxetine hydrochloride) full prescribing information. Available at: http://pi.lilly.com/ us/symbyax-pi.pdf. Last updated January 27, 2010. Accessed April 26, 2010.
48. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:118-27.
49. Linde K, Berner MM, Kriston L. St Johns wort for major depression. Cochrane Database Syst Rev 2008;4:CD000448.
50. Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009;71:235-42.
51. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361:799-808.
52. Kennedy SH, Milev R, Giacobbe P, et al; for the Canadian Network for Mood and Anxiety Treatments. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults: IV. Neurostimulation therapies. J Affect Disord 2009;117(suppl 1):S44-53.
53. Even C, Schroder CM, Friedman S, et al. Efficacy of light therapy in nonseasonal depression: a systematic review. Affect Disord 2008;108:11-23. (Pubitemid 351418015)
54. Levitt AJ, Joffe RT, Kennedy SH. Bright light augmentation in antidepressant nonresponders. J Clin Psychiatry 1991;52:336-7.
55. Spellman T, Peterchev AV, Lisanby SH. Focal electrically administered seizure therapy: a novel form of ECT illustrates the roles of current directionality, polarity, and electrode configuration in seizure induction. Neuropsychopharmacology 2009;34:2002-10.
56. Ward HE, Hwynn N, Okun MS. Update on deep brain stimulation for neuropsychiatric disorders. Neurobiol Dis 2010;38:346-53.
57. Bares M, Kopecek M, Novak T, et al. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a doubleblind, single-centre, randomized study. J Affect Disord 2009;118:94-100.
58. Dumitriu D, Collins K, Alterman R, et al. Neurostimulatory therapeutics in management of treatment-resistant depression with focus on deep brain stimulation. Mt Sinai J Med 2008;75:263-75.
59. Simon J, Pilling S, Burbeck R, et al. Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. Br J Psychiatry 2006;189:494-501. (Pubitemid 44876867)
60. Weihs KL, Settle EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000;61:196-202. (Pubitemid 30214516)
61. Unu tzer J, Katon W, Callahan CM, et al; for the IMPACT Investigators. Improving Mood-Promoting Access to Collaborative Treatment. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 2002;288: 2836-45. (Pubitemid 35425069)
62. Marcus SM. Depression during pregnancy: rates, risks and consequences. Can J Clin Pharmacol 2009;16:e15-22.
63. Soares CN. Practical strategies for diagnosing and treating depression in women: menopausal transition. J Clin Psychiatry 2008;69:e30.
64. Strong V, Waters R, Hibberd C, et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet 2008;372:40-8. (Pubitemid 351899234)
65. Walker J, Cassidy J, Sharpe M; for the SMaRT Oncology-2 Trialists. The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patients. Trials 2009;10:18.